ClinicalTrials.gg
Active, not recruitingNCT05899673Updated Nov 12, 2026

An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease

A Phase 3 interventional study of Fazirsiran Injection in Alpha1-Antitrypsin Deficiency, sponsored by Takeda. Active, not recruiting at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

How we know

Updated Nov 12, 2026Enrollment updatedEligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in alpha 1-Antitrypsin Deficiency by Takeda — 3 open to participants now, 4 under way, 3 of them phase 3. alpha 1-Antitrypsin Deficiency · Takeda.

Enrollment
Largest of 13
200 · median 30
Started
2023
with 1 other
Phase 3
5 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, this one has the largest enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 3, and was the 12th registered.

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Open to participants now

3 of the 14 studies in alpha 1-Antitrypsin Deficiency by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in alpha 1-Antitrypsin Deficiency by Takeda, or all of them as a file.
02

Study summary

The liver produces a protein called alpha-1 antitrypsin (AAT) which is released into the bloodstream. In some people, the liver makes an abnormal version of AAT, called Z-AAT. Z-AAT builds up in liver cells, and over time may lead to liver scarring (fibrosis), severe liver scarring (cirrhosis), and eventually end-stage liver disease. Fazirsiran is a medicine that reduces the production of the abnormal Z-AAT protein and its build-up in the liver.

The main aim of this study is to learn if fazirsiran is safe during long-term use in people with liver disease caused by the abnormal Z-AAT protein. People who have taken part in previous fazirsiran studies (AROAAT2001 [NCT03945292], AROAAT2002 [NCT03946449] , TAK-999-3001 [NCT05677971], or TAK-999-3002 [NCT06165341]) can continue to receive fazirsiran in this study. Participants will receive fazirsian every 3 months, along with health checks, as long as they participate in this study, the study is ongoing or until health authorities in their country approve fazirsiran to be publicly available. The study may also provide information on whether fazirsiran has a long-term effect in reducing liver fibrosis or slowing down the progression of liver fibrosis in people with liver disease due to the abnormal Z-AAT protein.

03

Conditions studied

  • Alpha1-Antitrypsin Deficiency
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria to be eligible for inclusion in the study:
  • The participant is willing and able to understand and fully comply with study procedures and requirements, in the opinion of the investigator.
  • The participant is able to read, understand, and complete the study questionnaires electronically per investigator's judgment.
  • The participant has provided (ICF) (that is, in writing, documented via a signed and dated ICF) and any required privacy authorization before the initiation of any study procedures.

Note: For participants who comprehend, can provide informed consent, and are unable to sign the ICF, an impartial witness may sign the ICF on behalf of the participant after the participant has orally consented to the participant's participation in the study.

  • The participant enrolling in this open-label extension (OLE) study will have participated in a previously qualifying study, and will be considered for eligibility based on the following study-specific criteria:
  • AROAAT2001:

    • Participants with fibrosis may roll over into this OLE study after they reach their next regularly scheduled, Q12W visit.
    • Participants with fibrosis who have completed the AROAAT2001 study may be enrolled into the OLE study.
  • AROAAT2002:

    • Participants in Cohorts 1 and 1b may roll over after completing the 24-week primary study period.
    • Participants in Cohort 2 may roll over after completing the 48-week primary study period.
    • Participants who have completed the study may be enrolled into the OLE study.
  • TAK-999-3001 and TAK-999-3002:

    • Participants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
  • The participant is a nonsmoker (defined as: does not smoke cigarettes daily for at least 24 weeks) with current nonsmoking status confirmed by urine cotinine at Day 1.

    • E-cigarettes (vapor) are not permitted.
    • The participant may be on nicotine replacement (patch or gum). A positive urine cotinine result due to nicotine replacement is acceptable for enrollment at the discretion of the investigator.
  • The participant must have suitable venous access for blood sampling.
  • It must be confirmed that the participant does not have hepatocellular carcinoma (HCC). Participants will be screened for HCC with alpha-fetoprotein (AFP) and abdominal ultrasound. If the participant has any of the following, they will be required to have contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) imaging to exclude HCC before enrollment.

    • AFP >20 nanogram per milliliter (ng/mL).
    • AFP 15 to 19 ng/mL at enrollment if that is >2 times prestudy levels (if available).
    • Any liver lesion >10 millimeter (mm) (longest diameter) detected by ultrasound.
    • Poor visibility of liver on ultrasound.
  • A person of (POCBP) must have a negative urine pregnancy test performed within 3 days prior to Day 1 dosing in this study (sensitive to 25 International Unit [IU] human chorionic gonadotropin [hCG]).
  • The participant must use appropriate methods (that is, highly effective methods for female and medically appropriate methods for male study participants) for the entire duration of the study. Participants who terminate early must use appropriate contraception methods for 6 months after the last dose of study intervention. Male participants who terminate early must not donate sperm for at least 6 months after the last dose of study intervention.
  • Sexual abstinence, for the purposes of this study, is only considered a highly effective method of contraception when considered to align with the preferred and usual lifestyle of the participant. It will be employed for the entire duration of the study and the 6 months after last dose of study intervention.
  • Periodic abstinence (calendar, symptothermal, postovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea methods are not considered "true" abstinence and are not acceptable methods of contraception.

Exclusion criteria

Exclusion Criteria:

  • The participant will be excluded from the study if any of the following exclusion criteria are met:
  • The participant is likely to require major surgery. Major surgery typically requires at least 1 night in the hospital. Examples include laparoscopic surgery (except cholecystectomy and tubal ligation); Gastrointestinal tract (GI) tract surgery including 1 or more segments of the colon or terminal ileum; open resection of organs; large joint replacements; mastectomy with reconstruction; and spine, thoracic, vascular, or intracranial surgery.
  • The participant has evidence of other forms of chronic liver diseases, including viral or C, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, alcoholic hepatitis, hemochromatosis, liver cancer, history of biliary diversion, or hepatitis.
  • The participant has abnormal finding(s) of clinical relevance during the evaluation before the first study dosing that, in the opinion of the investigator, could adversely impact participant safety during the study or adversely impact study results. For US only: Participants with baseline emphysema may be allowed into the OLE if their lung disease has been stable.
  • The participant had significant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002 that would affect the conduct of this study.
  • The participant permanently discontinued product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002.
  • Female participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of not agreeing to continue using appropriate methods through the conclusion of study participation.
  • The participant has a Child-Turcotte-Pugh (CTP) score >=7 OR (Model for End-Stage Liver Disease) MELD score >14.
  • The participant meets (ALT), Aspartate Aminotransferase (AST) and Creatinine criteria as per the protocol. All laboratory tests used as exclusion criteria may be repeated once and the repeat value may be used for study eligibility determination.
  • Participants who have a newly-diagnosed or recurrence of malignancy (except for resected cutaneous basal cell carcinoma, squamous cell carcinoma, superficial bladder tumors, or carcinoma in situ of the uterine cervix that has been treated with no evidence of recurrence).
  • The participant is experiencing a pulmonary exacerbation at the time of enrollment (participant enrollment may be temporarily delayed after the clinical resolution of an exacerbation).
  • The participant has unstable, poorly controlled, or severe hypertension. Participants may be reevaluated once their blood pressure is successfully controlled.
  • The participant has a history of more than moderate alcohol consumption within 12 months before the Day 1 visit.
  • The participant has a history of or allergies to fazirsiran or any associated .
  • The participant has any concomitant medical or psychiatric condition or social situation that would make it difficult to comply with protocol requirements or put the participant at additional safety risk.
  • The participant has a history of hematologic, renal, hepatic, cardiovascular, infectious, pulmonary, neurologic, psychiatric, GI, systemic inflammatory, metabolic, or endocrine disorder or any other condition that, in the opinion of the investigator, rendered the participant a poor candidate for inclusion into the study.
  • The participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
  • The participant is unable to return for all scheduled study visits.
  • Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
  • The participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
  • The participant who, in the opinion of the investigator or the sponsor, will be uncooperative or unable to comply with study procedures.
  • The participant who participates in other studies involving an investigational product.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Fazirsiran 200 mg

    Participants who are currently taking part in or who have completed their treatment in parent studies AROAAT2001 (NCT03945292), AROAAT2002 (NCT03946449), TAK-999-3001 \[NCT05677971\] and TAK-999-3002 (NCT06165341) will rollover in this study to receive fazirsiran, 200 milligrams (mg), injection, subcutaneously on Day 1 and once every 12 weeks (Q12W) thereafter until fazirsiran receives approval and is commercially available in the participant's country, until a participant withdraws from the study or the sponsor decides to terminate the study.

    Drug: Fazirsiran Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of the study intervention, whether or not it is considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study intervention. An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, suspected transmission of any infectious agent, an important medical event. AEs and SAEs including any pulmonary AEs or SAEs indicative of worsening pulmonary condition (example, pulmonary exacerbation, respiratory infection, significant pulmonary function test decline) will be reported.

    Time frame: From start of study drug administration (in current study) up to End of study (EOS) (current study [up to 10 years])

  2. Number of Participants With Clinically Significant Changes From Baseline in Pulmonary Function Parameters

    Standard pulmonary function parameters measured will be used to study lung function. Clinical significance of pulmonary function parameters will be determined at the investigator's discretion.

    Time frame: Baseline (current study), up to EOS (current study up to 10 years])

  3. Number of Participants With Clinically Significant Changes in Vital Signs

    Vital signs include body temperature, respiratory rate, sitting blood pressure (systolic and diastolic, resting more than 5 minutes), pulse, oxygen saturation. Clinical significance of vital signs will be determined at the investigator's discretion.

    Time frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

  4. Number of Participants With Clinically Significant Changes in Laboratory Parameters

    Laboratory parameters include hematology, biochemistry including liver tests, coagulation, and urinalysis. Clinical significance of laboratory parameters will be determined at the investigator's discretion.

    Time frame: From start of study drug administration (in current study) up to EOS (current study [up to 10 years])

Secondary outcomes

  1. Number of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102

    Number of participants from Studies AROAAT2001 and AROAAT2002 with no progression from baseline of at least 1 stage of histologic fibrosis (by Meta-Analysis of Histological Data in Viral Hepatitis \[METAVIR\] staging) on liver biopsy at Week 102 will be reported.

    Time frame: At Week 102 (current study)

  2. Number of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102

    Number of participants from Studies AROAAT2001 and AROAAT2002 with baseline fibrosis of F1 or higher, a decrease from baseline of at least 1 stage of histologic fibrosis (by METAVIR staging) on liver biopsy at Week 102 will be reported.

    Time frame: At Week 102 (current study)

  3. Change from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102

    Change from baseline in intrahepatic Z-AAT protein polymer burden assessed by PAS+D staining in liver biopsy for participants from Studies AROAAT2001 and AROAAT2002 will be assessed.

    Time frame: Baseline (current study), Week 102 (current study)

  4. Change from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy

    Change in portal inflammation score in liver biopsy, based on pathology slide reads for participants from Studies AROAAT2001 and AROAAT2002 will be assessed. Inflammation will be assessed on a scale of 0-3, with higher scores showing more severe inflammation.

    Time frame: Baseline (current study), Week 102 (current study)

  5. Change from Baseline in Liver Stiffness Assessed by Magnetic Resonance Elastography (MRE)

    Change from baseline in MRE-derived liver stiffness will be assessed.

    Time frame: Baseline (current study), up to EOS (current study up to 10 years])

  6. Change from Baseline in Liver Stiffness Assessed by Vibration-Controlled Transient Elastography (VCTE)

    Change from baseline in VCTE-derived liver stiffness will be assessed.

    Time frame: Baseline (current study), up to EOS (current study up to 10 years])

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2023 (actual). Primary completion is estimated for May 2033, 116 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2023
First posted
Jun 12, 2023
StartActual
Aug 8, 2023
Primary completionEst.
May 2, 2033
CompletionEst.
May 2, 2033
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
31→200
Nov 12, 2026
Eligibility
2 inclusion criteria added; 6 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • AddedTAK-999-3001 and TAK-999-3002:
  • AddedParticipants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
Exclusion criteria
  • EditedThe participant had majorsignificant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002 that would affect the conduct of this study.
  • EditedThe participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002.
  • EditedFemale participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
  • EditedThe participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
  • ChangedBefore The participant has known or suspected coronavirus disease 2019 (COVID-19) that in the opinion of the sponsor and investigator does not resolve during screening. Positive antibody testing for COVID-19 without other evidence of current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infection may be temporarily delayed at the discretion of the sponsor and investigator. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.Now Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
  • EditedThe participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
Nov 12, 2026
Secondary outcomes
4 description edited
What changed in the outcomes
  • DescriptionChange from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy: how it is measured was reworded
  • DescriptionChange from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102: how it is measured was reworded
  • DescriptionNumber of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102: how it is measured was reworded
  • DescriptionNumber of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102: how it is measured was reworded
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Enrollment 31→200
    Eligibility 2 inclusion criteria added; 6 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • AddedTAK-999-3001 and TAK-999-3002:
    • AddedParticipants who have completed the treatment period in Study TAK-999-3001 or TAK-999-3002.
    Exclusion criteria
    • EditedThe participant had majorsignificant protocol deviation(s) in Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002 that would affect the conduct of this study.
    • EditedThe participant permanently discontinued investigational product because of an AE, adjudicated as related to the study intervention, in Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002.
    • EditedFemale participants who became pregnant during Study AROAAT2001, AROAAT2002, TAK-999-3001, or AROAAT2002TAK-999-3002, female participants who are lactating or planning to become pregnant during the study period; or males or female participants of childbearing potential not agreeing to continue using appropriate contraception methods through the conclusion of study participation.
    • EditedThe participant has a history of thromboembolic disease (including deep vein thrombosis or pulmonary embolism), within 24 weeks before enrollment; or is taking chronic anticoagulants. (Note: Participants taking stable doses of chronic anticoagulants may be allowed after consultation with the medical monitor, if they do not have cirrhosis or a history of liver decompensating events). Low-dose aspirin may be permitted on-study with the approval of the participant's local healthcare providers and discussion with study medical monitors.
    • ChangedBefore The participant has known or suspected coronavirus disease 2019 (COVID-19) that in the opinion of the sponsor and investigator does not resolve during screening. Positive antibody testing for COVID-19 without other evidence of current or recent active infection does not exclude participation. Enrollment of participants who fail inclusion due to COVID-19 infection may be temporarily delayed at the discretion of the sponsor and investigator. If the participant has a positive polymerase chain reaction (PCR) with no other evidence of infection, a retest may be allowed; however, to enroll in the study the participant must have a negative PCR.Now Enrollment of participants with symptomatic coronavirus disease 2019 (COVID-19) infection may be temporarily delayed at the discretion of the sponsor and investigator. Positive antibody testing for COVID-19 without other evidence of symptomatic current or recent active infection does not exclude participation.
    • EditedThe participant is a study site employee involved in the conduct of this study, an immediate family member (for example, spouse, parent, child, sibling), or is in a dependent relationship with a study site employee who is involved in conduct of this study, or may consent under duress.
    Secondary outcomes 4 description edited
    What changed in the outcomes
    • DescriptionChange from Baseline in Intrahepatic Portal Inflammation Score at Week 102 in Liver Biopsy: how it is measured was reworded
    • DescriptionChange from Baseline in Intrahepatic Z-AAT Protein Polymer Burden Assessed by Periodic Acid Schiff Plus Diastase (PAS+D) Staining in Liver Biopsy at Week 102: how it is measured was reworded
    • DescriptionNumber of Participants With Reduction from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102: how it is measured was reworded
    • DescriptionNumber of Participants With no Progression from Baseline of At least 1 Stage of Histologic Fibrosis on Liver Biopsy at Week 102: how it is measured was reworded
    + 5 other changes: identifiers, verification date, description, arm descriptions and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05899673
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Aug 8, 2023
Primary completion
May 2, 2033 (estimated)
Completion
May 2, 2033 (estimated)
Last update
Nov 12, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fazirsiran

Start the discussion